Earnings News - Candlesense

Docusign Announces Timing of Second Quarter Fiscal 2026 Earnings Conference Call

SAN FRANCISCO, Aug. 14, 2025 /PRNewswire/ -- Docusign (Nasdaq: DOCU) today announced that its second quarter fiscal 2026 results will be released on Thursday, September 4, 2025, after the close of ...

What is the expected impact of the earnings release on DOCU's stock liquidity and order flow, and how should I position my trades around the call? Will the company address any recent regulatory developments or competitive pressures that could affect its growth trajectory? How might macro‑economic factors (e.g., interest rates, corporate spending trends) influence DOCU's performance and the market's reaction to the earnings release?

Symbol: DOCU

26 days ago

Talphera Announces Second Quarter 2025 Financial Results and Provides Corporate Update

New sites accelerate registrational study enrollment - 15 patients have been enrolled in the NEPHRO study which remains on track with completion projected by the end of the year Cash and cash equiv...

How might the sentiment score of 35 influence short‑term trader sentiment and volatility in the stock? What is the market’s reaction to the conference call, and are there any red‑flag comments from management regarding risks or delays? How does TRIA’s valuation metrics (e.g., P/E, EV/EBITDA) look after this earnings release relative to peers in the nephrology biotech space?

Symbol: TRIA

26 days ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2025

PORTLAND, Maine, Aug. 14, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scien...

How might the quarter's results influence valuation multiples (e.g., P/E, EV/EBITDA) for ICCC moving forward? What are the implications of the high sentiment score (10) for investor sentiment and potential buying pressure? Are there any significant R&D or capital‑expenditure initiatives disclosed that could affect future earnings?

Symbol: ICCC

26 days ago

Read more globenewswire

CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights

CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-tar...

How does the current share float and insider ownership affect potential price movement and short‑interest dynamics? Are there any upcoming catalysts (e.g., FDA meetings, data readouts) that could drive short‑term price volatility? Did the company announce any new partnerships, licensing agreements, or collaborations that could impact revenue or dilution?

Symbol: CAMP

26 days ago

Read more globenewswire

GT Biopharma Reports Second Quarter 2025 Financial Results

SAN FRANCISCO, CALIFORNIA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeut...

How might the reported results influence short‑term technical analysis indicators, such as moving averages or volume trends? Is there any indication of regulatory milestones or FDA interactions that could affect the timeline for product commercialization? What were the primary drivers behind any variance in operating expenses versus the prior quarter or year‑over‑year?

Symbol: GTBP

26 days ago

Read more globenewswire

TOMI Environmental Solutions, Inc. Reports Q2 2025 Financial Results and Outlines Growth Initiatives

FREDERICK, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global provider of disinfection and decontamination essentials through its premier Binary Io...

How does the current sentiment score (30) reflect market perception, and could it signal a buying or selling opportunity? Are there any upcoming catalyst events (e.g., product launches, partnership announcements, conference presentations) that could drive further price movement? What is the expected impact of the growth initiatives on the company's earnings per share (EPS) and revenue forecasts for the next 12‑24 months?

Symbol: TOMZ

26 days ago

Read more globenewswire

authID Reports Financial and Operating Results for the Second Quarter 2025; Delivers the Highest Revenue in the Company’s History

DENVER, Aug. 14, 2025 (GLOBE NEWSWIRE) -- authID® (Nasdaq: AUID) (“authID” or the “Company”), a leading provider of biometric identity verification and authentication solutions, today reported fi...

Are there any risks or uncertainties highlighted in the MD&A that could impact the stock's volatility? Does the company provide any updates on its customer pipeline, contract wins, or partnership developments that could drive future revenue? What regulatory or macroeconomic factors could influence the company's performance moving forward?

Symbol: AUID

26 days ago

Read more globenewswire

Venus Concept Announces Second Quarter 2025 Financial Results

TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the ...

What risk factors (e.g., regulatory, supply chain, litigation) were highlighted in the filing, and how might they affect the stock’s risk profile? Are there any notable changes in the competitive landscape (e.g., competitor earnings, market share shifts) that could impact Venus Concept’s market position? How does the company's valuation (P/E, EV/EBITDA, price/earnings growth) compare to other medical aesthetic technology companies?

Symbol: VERO

26 days ago

Read more globenewswire

Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

REDWOOD CITY, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cance...

What is the current shareholder composition and are there any upcoming lock‑up expirations or insider sales that could affect share supply? How will the expansion of the BDC-4182 trial to other countries affect cash burn and operational risk? What are the potential regulatory hurdles for the next‑generation Boltbody™ ISAC platform, and how might they affect timeline and valuation?

Symbol: BOLT

26 days ago

Read more globenewswire

Profound Medical Announces Second Quarter 2025 Financial Results

TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customi...

What are the potential risks or headwinds highlighted in the MD&A that could affect future performance? Did the company disclose any significant contract wins, partnerships, or supply‑chain updates that could affect future revenue? What is the impact of foreign‑exchange fluctuations and other non‑recurring items on the results?

Symbol: PROF

26 days ago

Read more globenewswire